Drug Development

Former FDA commissioner Califf to pharma: opening up on health data requires overcoming risk

Former FDA commissioner Califf to pharma: opening up on health data requires overcoming risk

By

Califf spoke about the importance of more data to faster and cheaper drug development at the NewYorkBIO conference.

The infectious disease doctor mining the microbiome for drugs

The infectious disease doctor mining the microbiome for drugs

By

How Seres CEO Roger Pomerantz went from an infectious disease doctor to mining the microbiome for drugs.

Has DTC in the oncology space kept up with science?

Has DTC in the oncology space kept up with science?

By

As oncology drugs save or extend the lives of many more patients than anyone could have imagined a few years ago, a new challenge has emerged in the wake of their approval: Selling them to patients scared about their prognosis and alternately ignorant of and skeptical about recent breakthroughs in treatment.

 Five things for pharma marketers to know: Wednesday, February 21, 2018

Five things for pharma marketers to know: Wednesday, February 21, 2018

AbbVie reports successful elagolix trial; White House touts short-term insurance plans; Mayo Clinic chief to retire.

Five things for pharma marketers to know: Wednesday, February 14, 2018

Five things for pharma marketers to know: Wednesday, February 14, 2018

IPG 2017 net income drops; Bristol-Myers Squibb inks $1.85 billion deal with Nektar on cancer drug; Merck halts final-stage Alzheimer's drug.

New tactics change clinical trial awareness game

New tactics change clinical trial awareness game

By

Recruitment for clinical trials has never been easy. New tools and tactics could change that — assuming the sheer volume of information doesn't overwhelm trial organizers.

Five things for pharma marketers to know: Thursday, January 11, 2018

Five things for pharma marketers to know: Thursday, January 11, 2018

By

Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations

Five things for pharma marketers to know: Friday, December 8, 2017

Five things for pharma marketers to know: Friday, December 8, 2017

By

FDA approves first nebulized LAMA COPD treatment; more than 2,000 cancer immunotherapies in development; FDA issues 3D-printing guidance

First 'Digital Drug' Faces a Second Litmus Test: Improving Adherence

First 'Digital Drug' Faces a Second Litmus Test: Improving Adherence

By

Technology like this could expand further to form better collaborations between pharma, payers and organized providers.

Five things for pharma marketers to know: Tuesday, November 14, 2017

Five things for pharma marketers to know: Tuesday, November 14, 2017

By

FDA approves first digital pill; biotech companies race to develop cancer-fighting microbiome drugs; Loxo and Bayer reach $1.55 billion deal for rare cancer drugs

Five things for pharma marketers to know: Friday, September 29, 2017

Five things for pharma marketers to know: Friday, September 29, 2017

By

Merck to stop developing hep.-C drugs; FDA approves new Lilly breast-cancer drug; California bill would outlaw co-pay cards

Study says drug development costs much less than previously estimated

Study says drug development costs much less than previously estimated

By

New research suggests that the oft-cited $2.6 billion estimate for bringing a drug to market is significantly overstated.

Five things for pharma marketers to know: Friday, April 22, 2016

Five things for pharma marketers to know: Friday, April 22, 2016

By

AstraZeneca to sequence two million genomes; Valeant considering Perrigo CEO as its new chief executive; AMA and PhRMA each spent $6 million on lobbying

Top 25 orphan drugs, by 2015 global sales

Top 25 orphan drugs, by 2015 global sales

Roche's Rituxan generated $7.3 billion in sales in 2015, making it the top-selling orphan drug.